全文获取类型
收费全文 | 1737505篇 |
免费 | 141352篇 |
国内免费 | 2963篇 |
专业分类
耳鼻咽喉 | 23542篇 |
儿科学 | 57342篇 |
妇产科学 | 49190篇 |
基础医学 | 246139篇 |
口腔科学 | 53888篇 |
临床医学 | 151157篇 |
内科学 | 344710篇 |
皮肤病学 | 37664篇 |
神经病学 | 141613篇 |
特种医学 | 68922篇 |
外国民族医学 | 498篇 |
外科学 | 260781篇 |
综合类 | 40862篇 |
现状与发展 | 4篇 |
一般理论 | 598篇 |
预防医学 | 137854篇 |
眼科学 | 39068篇 |
药学 | 129590篇 |
2篇 | |
中国医学 | 3529篇 |
肿瘤学 | 94867篇 |
出版年
2018年 | 18928篇 |
2017年 | 14690篇 |
2016年 | 15776篇 |
2015年 | 18379篇 |
2014年 | 25377篇 |
2013年 | 37253篇 |
2012年 | 51749篇 |
2011年 | 54430篇 |
2010年 | 31260篇 |
2009年 | 29610篇 |
2008年 | 50293篇 |
2007年 | 53065篇 |
2006年 | 53227篇 |
2005年 | 52077篇 |
2004年 | 51079篇 |
2003年 | 48488篇 |
2002年 | 45956篇 |
2001年 | 78940篇 |
2000年 | 81652篇 |
1999年 | 69350篇 |
1998年 | 18899篇 |
1997年 | 17305篇 |
1996年 | 17263篇 |
1995年 | 16809篇 |
1994年 | 15866篇 |
1993年 | 14983篇 |
1992年 | 57205篇 |
1991年 | 55499篇 |
1990年 | 54191篇 |
1989年 | 52463篇 |
1988年 | 48743篇 |
1987年 | 47944篇 |
1986年 | 45570篇 |
1985年 | 44085篇 |
1984年 | 32920篇 |
1983年 | 28312篇 |
1982年 | 16569篇 |
1981年 | 14808篇 |
1979年 | 31155篇 |
1978年 | 21542篇 |
1977年 | 18127篇 |
1976年 | 16993篇 |
1975年 | 18006篇 |
1974年 | 21907篇 |
1973年 | 21109篇 |
1972年 | 19209篇 |
1971年 | 18078篇 |
1970年 | 16669篇 |
1969年 | 15615篇 |
1968年 | 14296篇 |
排序方式: 共有10000条查询结果,搜索用时 578 毫秒
141.
142.
R. E. J. Ryder 《Diabetic medicine》2015,32(3):305-313
On 8 April 2014, a US jury ordered Takeda and Eli Lilly to pay $9 bn in punitive damages after finding that they had concealed the cancer risks associated with pioglitazone. By contrast, on 28 August 2014, the long‐awaited outcome of the 10‐year Kaiser Permanente Northern California study was announced. That study was specifically designed to investigate whether patients exposed to pioglitazone were at an increased risk of bladder cancer and found no association; thus, at last, the controversial issue has been resolved. A review, in retrospect, of the story of the proposed link between pioglitazone and bladder cancer reveals flaws at every stage. In 2012, a BMJ editorial, in keeping with some other contemporary reports, stated ‘it can confidently be assumed that pioglitazone increases the risk of bladder cancer’. Examination of the information which led to such a statement shows that: 1) the pre‐clinical findings of bladder cancer in male rats is not indicative of human risk; 2) there is no association between bladder cancer and pioglitazone in randomized controlled trials, once cases that could not plausibly be related to treatment are removed; and 3) the observational studies that have suggested a link have over‐extrapolated from the data: pioglitazone‐treated patients had more risk factors for bladder cancer than those not treated with pioglitazone. Meanwhile careful study of randomized controlled trials shows evidence of cardiovascular benefit from pioglitazone in Type 2 diabetes, a condition which results, more than anything, in premature cardiovascular death and morbidity. 相似文献
143.
144.
M. Alexandra Friedman Charlotte M. Niznik Janelle R. Bolden Lynn M. Yee 《Journal of community health》2016,41(2):354-358
While peer support has been investigated in multiple clinical contexts, its application to the postpartum setting is unknown. The aim was to assess acceptability of a postpartum peer support program for women with diabetes. Observational survey-based needs assessment of forty low-income women with diabetes, receiving care at a major medical institution. Mean age and gravidity were 30.7 years and 3.15 ± 1.67 respectively. 45 % expressed interest in a “buddy.” There was no significant difference between groups desiring and not desiring this program. A majority of respondents desired telephone, text messaging, and in-person contacts (79.2, 72.1, 83.8 %), with 72.5 % of patients desiring diabetes-related activities during clinic waiting time. Many women desire a postpartum diabetes reciprocal peer program for support outside of clinician visits. Patients are receptive to educational services during their wait and outside of clinic time, a potentially valuable opportunity to share important health information. 相似文献
145.
146.
147.
Turnbull Chris D. Stockley James A. Madathil Shyam Huq Syed S. A. Cooper Brendan G. Ali Asad Wharton Simon Stradling John R. Heitmar Rebekka 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(7):2129-2139
Graefe's Archive for Clinical and Experimental Ophthalmology - Retinal microvascular endothelial dysfunction is thought to be of importance in the development of ocular vascular diseases.... 相似文献
148.
Caio Henrique de Carvalho Assuno Júlio Csar Trabanco Raquel Fornaziero Gomes Renata Rodrigues Moreira Alessandra Giannella Samelli 《La Medicina del lavoro》2019,110(4):304
Objective:The present study evaluates a training program for fitting different hearing protection devices (HPDs) based on personal attenuation rating (PAR) before, immediately after, and six months after training.Methods:A total of 67 workers from a public university in the city of São Paulo, Brazil, were invited to participate in the measurement of PARs for foam and silicone protectors through the 3M™ E-A-Rfit Validation System. Two evaluations were performed for each protector at each sampling date: one after reading printed material (the package instructions) and another after being trained by an audiologist. The same procedures were repeated after six months. The final sample consisted of 30 individuals. ANOVA was used for statistical analysis.Results:Larger PAR values were observed after training by the audiologist, and smaller values were observed after six months. Then, after re-training, the values increased again. There were no statistically significant differences in PAR among the HPDs tested. Even after the two training sessions, 23 to 27% of the subjects did not obtain adequate PAR values.Conclusion:These findings emphasize the need for continual worker training in the correct fit of earplug HPDs and the importance of longitudinal PAR monitoring. In addition, some workers, despite the training provided, did not adapt to the HPDs used. Therefore, it is essential that other protection methods and/or other HPD types are made available to these individuals.Key words: Hearing, noise-induced hearing loss, occupational health, personal protective equipment, hearing protection devices 相似文献
149.
150.
The term “oligometastatic prostate cancer” refers to a heterogeneous group of disease states currently defined solely on the basis of clinical features. Oligorecurrent disease, de novo oligometastases, and oligoprogressive disease likely have unique biologic underpinnings and natural histories. Evidence suggesting the existence of a subset of patients who harbor prostate cancer with limited metastatic potential currently includes disparate and overwhelmingly retrospective reports. Nevertheless, emerging prospective data have corroborated the “better-than-expected,” retrospectively observed outcomes, particularly in the setting of oligorecurrent prostate cancer. Improved functional imaging with prostate-specific membrane antigen-targeted strategies may enhance the identification of patients with oligometastatic prostate cancer in the short term. In the long term, refinement of the oligometastatic case definition likely will require biologic risk-stratification schemes. To determine optimal treatment strategies and identify patients most likely to benefit from metastasis-directed therapy, future efforts should focus on conducting high-quality, prospective trials with much-needed molecular correlative studies. 相似文献